Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL PatientsRocket Trial
Status:
RECRUITING
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of orelabrutinib combined with the R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) regimen as first-line treatment in CD5-positive diffuse large B-cell lymphoma (DLBCL) patients.
Phase:
PHASE2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Dongguan People's Hospital Fifth Affiliated Hospital of Guangzhou Medical University Fifth Affiliated Hospital, Sun Yat-Sen University First Affiliated Hospital of Shantou University Medical College Gansu Cancer Hospital Guangdong Provincial Hospital of Traditional Chinese Medicine Guangzhou First People's Hospital Second Affiliated Hospital of Guangzhou Medical University Shenzhen People's Hospital Southern Medical University, China The First People's Hospital of Zhaoqing